DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies ...

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV - ISIN: FR0010417345 ...

CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition ...

This isn’t just an animal health crisis — it’s a risk to public health. When animals consume foods containing live virus, ...

The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing ...

Sanofi’s tolebrutinib has been shown to delay disability progression in multiple sclerosis (MS) patients, according to phase ...

A scientific statement has been published by the AHA regarding cardiovascular toxicity in patients treated for childhood cancer.

Fungi-focused biotech LifeMine Therapeutics is slimming down its staff and consolidating its operations to dig into clinical ...

Omeros (NASDAQ:OMER – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Monday, ...

Eli Lilly focuses on genetic medicine, developing treatments for diabetes, heart disease, deafness, Parkinson's, and Alzheimer's. Expanding in India.

Q4 2024 Earnings Call Transcript March 27, 2025 INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.4, expectations were $-0.54. Operator: Greetings, and welcome to the INmune Bio’s.